Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003170 · ClinicalTrials.gov registry record · Phase 3
Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 129
- Enrollment target
NCT00003170 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 129 participants.
The verdict
NCT00003170, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 129 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Glutamine may be an effective treatment for acute diarrhea caused by radiation therapy. It is not known if glutamine is an effective treatment for acute diarrhea caused by radiation therapy. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of glutamine in preventing acute diarrhea in patients who have pelvic cancer and who are receiving radiation therapy.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 1998-02 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003170
The ClinicalTrials.gov registry entry for NCT00003170 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00003170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003170 about?
NCT00003170 is a clinical study titled "Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Glutamine may be an effective treatment for acute diarrhea caused by radiation therapy. It is not known if glutamine is an effective treatment for acute diarrhea caused by radiation therapy. PURPOSE: Randomized double-blind...
What is the current status of trial NCT00003170?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 1998-02. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00003170?
The interventions under investigation include: placebo (OTHER), glutamine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00003170?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.